AstraZeneca has taken on Brazilian rights to UCB’s Cimzia®, approved in the U.S. for rheumatoid arthritis (RA) and Crohn’s disease. AstraZeneca may also distribute line extensions related to Cimzia in Brazil, while UCB retains the right to co-promote Cimzia and line extensions in the country.
UCB is developing Cimzia in other autoimmune disease like lupus as well as fracture healing and post-menopausal osteoporosis. The drug is at the Phase II stage for all indications.
AstraZeneca is responsible for registration and upon approval will be the exclusive distributor of Cimzia, an PEGylated anti-TNF alpha compound in Brazil. Initial registration activities will focus on RA and Crohn’s.